The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2025 Feb 13

PMID 39947253

Authors

Chengyuan Li

Yucheng Xue

Eloy Yinwang

Zhaoming Ye

Affiliations

Soon will be listed here.

Abstract

Background: MDSCs are immature neutrophils and monocytes with immunosuppressive potentials, involving mononuclear MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs).

Recent Findings: They are significant components of the tumor microenvironment (TME). Besides, recent studies also verified that MDSCs also facilitated the progression of bone metastasis by regulating the network of cytokines and the function of immune cells.

Conclusion: It is necessary to summarize the mechanisms of MDSC recruitment and immunosuppression, and their impact on bone metastasis.

References

Allaoui R, Bergenfelz C, Mohlin S, Hagerling C, Salari K, Werb Z . Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat Commun. 2016; 7:13050. PMC: 5062608. DOI: 10.1038/ncomms13050. View

Lu Z, Zou J, Li S, Topper M, Tao Y, Zhang H . Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature. 2020; 579(7798):284-290. PMC: 8765085. DOI: 10.1038/s41586-020-2054-x. View

Henrich S, McMahon K, Plebanek M, Calvert A, Feliciano T, Parrish S . Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner. J Extracell Vesicles. 2021; 10(2):e12042. PMC: 7775568. DOI: 10.1002/jev2.12042. View

Cai J, Cui Y, Yang J, Wang S . Epithelial-mesenchymal transition: When tumor cells meet myeloid-derived suppressor cells. Biochim Biophys Acta Rev Cancer. 2021; 1876(1):188564. DOI: 10.1016/j.bbcan.2021.188564. View

Legitimo A, Consolini R, Failli A, Orsini G, Spisni R . Dendritic cell defects in the colorectal cancer. Hum Vaccin Immunother. 2014; 10(11):3224-35. PMC: 4514061. DOI: 10.4161/hv.29857. View

Highfill S, Rodriguez P, Zhou Q, Goetz C, Koehn B, Veenstra R . Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood. 2010; 116(25):5738-47. PMC: 3031417. DOI: 10.1182/blood-2010-06-287839. View

Nakamura K, Smyth M . Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2019; 17(1):1-12. PMC: 6952382. DOI: 10.1038/s41423-019-0306-1. View

Alfaro C, Teijeira A, Onate C, Perez G, Sanmamed M, Andueza M . Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clin Cancer Res. 2016; 22(15):3924-36. DOI: 10.1158/1078-0432.CCR-15-2463. View

Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim R, Ong S . Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer. Cancer Res. 2021; 81(12):3295-3308. PMC: 8776246. DOI: 10.1158/0008-5472.CAN-20-3564. View

10.

Delano M, Scumpia P, Weinstein J, Coco D, Nagaraj S, Kelly-Scumpia K . MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007; 204(6):1463-74. PMC: 2118626. DOI: 10.1084/jem.20062602. View

11.

Cervantes-Villagrana R, Albores-Garcia D, Cervantes-Villagrana A, Garcia-Acevez S . Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. Signal Transduct Target Ther. 2020; 5(1):99. PMC: 7303203. DOI: 10.1038/s41392-020-0205-z. View

12.

Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L . Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J Clin Invest. 2018; 128(12):5479-5488. PMC: 6264739. DOI: 10.1172/JCI120156. View

13.

Ma Z, Zhao X, Deng M, Huang Z, Wang J, Wu Y . Bone Marrow Mesenchymal Stromal Cell-Derived Periostin Promotes B-ALL Progression by Modulating CCL2 in Leukemia Cells. Cell Rep. 2019; 26(6):1533-1543.e4. DOI: 10.1016/j.celrep.2019.01.034. View

14.

Sawant A, Ponnazhagan S . Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res. 2013; 73(15):4606-10. PMC: 3732563. DOI: 10.1158/0008-5472.CAN-13-0305. View

15.

Anwar M, Shah M, Kim J, Choi S . Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev. 2018; 39(3):1053-1090. PMC: 6587958. DOI: 10.1002/med.21553. View

16.

Mizutani K, Sud S, McGregor N, Martinovski G, Rice B, Craig M . The chemokine CCL2 increases prostate tumor growth and bone metastasis through macrophage and osteoclast recruitment. Neoplasia. 2009; 11(11):1235-42. PMC: 2767225. DOI: 10.1593/neo.09988. View

17.

Gorrini C, Harris I, Mak T . Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013; 12(12):931-47. DOI: 10.1038/nrd4002. View

18.

Wu K, Feng J, Lyu F, Xing F, Sharma S, Liu Y . Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nat Commun. 2021; 12(1):5196. PMC: 8408156. DOI: 10.1038/s41467-021-25473-y. View

19.

Talmadge J . Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res. 2007; 13(18 Pt 1):5243-8. DOI: 10.1158/1078-0432.CCR-07-0182. View

20.

Guo Y, Liu Y, Wu W, Ling D, Zhang Q, Zhao P . Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials. 2021; 276:121018. DOI: 10.1016/j.biomaterials.2021.121018. View